GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.78 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.150B Est

Loading news article.

GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.78 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.150B Est | WAPE

Article summary